top of page

What Are the Top 10 Best Probiotic Blends?

5 days ago
25 min read

Updated: 5 hours ago

Probiotics have become an important area of research in gut microbiome science, nutritional supplements and functional food development. As scientific understanding of the human microbiome expands, manufacturers are increasingly exploring combinations of probiotic microorganisms to develop products for digestive health, bowel regularity, antibiotic-associated gastrointestinal concerns and other applications.


One question frequently asked by consumers, supplement brands and product developers is:


What are the top 10 best probiotic blends?


The answer requires an important scientific distinction: there is no universally accepted ranking of the ten best probiotic blends for every person or application.


A probiotic formulation that has been investigated for one health outcome may not be appropriate for another. The effectiveness of a product depends on the identity of its microorganisms, the specific strains used, the dose, the target population, the formulation and the quality of the supporting clinical evidence.


The internationally accepted definition of a probiotic is a live microorganism that, when administered in adequate amounts, confers a health benefit on the host. This definition was established in a consensus statement published in Nature Reviews Gastroenterology & Hepatology and remains a foundational principle for probiotic research and product development [1].


Consequently, a product containing ten different bacterial strains is not necessarily better than one containing two carefully selected strains. Likewise, a high colony-forming unit (CFU) count does not, by itself, establish that a product is more effective.


The most useful way to identify the top probiotic blends is to evaluate scientifically justified formulation categories, the strains used, the intended application and the quality of the available evidence.


This article examines ten promising probiotic blend categories, explains the microorganisms commonly investigated in each, discusses the relevant clinical evidence, and provides practical guidance for formulation, quality control and commercial product development.


The article is intended as an educational and scientific resource. The ten categories below are not a validated numerical ranking, and they should not be interpreted as proof that every formulation containing the listed microorganisms will produce the described effects.


How Should We Define the Top 10 Best Probiotic Blends?


Before comparing formulations, it is important to establish what makes a probiotic blend scientifically valuable.


A useful assessment should consider five major factors.


Clinical evidence


The strongest starting point is human clinical research relevant to the intended application.

Randomised controlled trials and systematic reviews can help establish whether a formulation improves a defined outcome. However, trial quality, study size, consistency of findings and relevance to the intended population must be considered.


A systematic review of probiotic research found that efficacy varies according to both the strain and the condition being investigated. The authors cautioned that pooling different probiotics can produce misleading conclusions when their characteristics and effects differ [2].


Strain identity


A probiotic should be identified at an appropriate taxonomic level, with a strain designation where applicable.


For example, Lacticaseibacillus rhamnosus GG is a specific strain, not a synonym for every L. rhamnosus strain.


Scientific findings for one strain should not automatically be applied to another strain of the same species.


Formulation compatibility


The microorganisms must remain suitable for use when combined.

Different strains can vary in their sensitivity to moisture, oxygen, temperature and other formulation conditions. A blend therefore needs an appropriate compatibility and stability assessment.


Manufacturing quality


The finished product should meet suitable specifications for identity, viable count, microbiological quality and shelf life.


A product with a compelling scientific rationale is not commercially suitable if it cannot consistently meet its quality specifications.


Intended application


The formulation should be selected according to its intended use.

For example, evidence relating to antibiotic-associated diarrhoea should not automatically be used to justify a claim concerning constipation, skin health or metabolic health.


The following ten categories are therefore best understood as a scientifically informed shortlist of probiotic blend strategies, rather than a definitive ranking of commercial products.


Top 10 Probiotic Blend Categories: A Scientific Comparison


The table provides an overview of ten formulation strategies worth investigating.

No.

Probiotic blend category

Commonly investigated microorganisms or ingredients

Principal research area

Key consideration

1

Lactobacillus–Bifidobacterium blend

Selected strains of Lactobacillus-related genera and Bifidobacterium

Digestive and gastrointestinal outcomes

Evidence must support the specific combination

2

Multi-strain gastrointestinal blend

Selected Lactobacillaceae and Bifidobacteriaceae strains

Symptoms associated with irritable bowel syndrome (IBS)

Clinical findings are inconsistent across formulations

3

Antibiotic-associated diarrhoea formulation

Selected strains such as L. rhamnosus GG, or specific yeast probiotics

Prevention of antibiotic-associated diarrhoea

Evidence is strain- and population-specific

4

Bifidobacterium-dominant blend

Selected Bifidobacterium strains

Microbiome and gastrointestinal research

Species or genus identity alone does not establish efficacy

5

Lactobacillus-dominant blend

Selected strains from relevant Lactobacillaceae genera

Gastrointestinal and other strain-specific applications

Strain selection is more important than the genus name

6

Spore-forming Bacillus blend

Selected Bacillus strains

Gastrointestinal research and formulation development

Strain-specific safety and quality assessment are essential

7

Bacterial–yeast probiotic formulation

Selected bacterial strains and a characterised probiotic yeast

Applications studied for particular gastrointestinal outcomes

Compatibility, clinical evidence and safety require evaluation

8

Paediatric gastrointestinal formulation

Selected strains studied in children

Specific paediatric gastrointestinal applications

Evidence must match the age group and indication

9

Probiotic–prebiotic synbiotic formulation

Selected probiotics plus a suitable substrate

Microorganism–substrate interactions

Must meet the scientific criteria for a synbiotic

10

Clinically substantiated, application-specific blend

A defined combination supported by relevant research

A clearly specified target outcome

Evidence for the actual formulation is essential

This comparison does not imply that all ten categories have equally strong evidence. Some are broad formulation approaches; others describe more specific research strategies.

The most appropriate choice depends on the evidence available for the exact ingredients and intended use.

Bifidobacterium longum powder for Lactobacillus–Bifidobacterium probiotic blends
Lactobacillus–Bifidobacterium blends are among the most widely developed multi-strain formulas.

Blend No. 1: Lactobacillus–Bifidobacterium Probiotic Blends


What are Lactobacillus–Bifidobacterium blends?

Lactobacillus–Bifidobacterium blends combine selected strains from two groups of bacteria frequently investigated in probiotic research: Lactobacillus and Bifidobacterium.

They are widely considered in the development of multi-strain supplements because the groups contain microorganisms with different physiological and technological characteristics.

Depending on the strains selected, a formulation may be designed for general nutritional use or investigated for a specific gastrointestinal outcome.


However, it is important not to assume that every member of either group has the same biological properties.


The genus Lactobacillus underwent extensive taxonomic revision in 2020. Several species were assigned to new genera, including Lacticaseibacillus, Lactiplantibacillus and Limosilactobacillus. Consequently, older scientific publications may use names that differ from those currently accepted [3].


Commonly investigated strains


Potential candidates include characterised strains of:

These are examples of organisms studied in probiotic research, not a recommendation to combine all of them in one product.


The suitability of each strain depends on its identity, evidence, safety, technical properties and intended application.


Why are these combinations investigated?


A multi-strain formulation allows product developers to combine microorganisms with different characteristics.


Researchers may investigate whether a particular combination influences gastrointestinal symptoms, microbial composition or other predefined outcomes.


A randomised, double-blind, placebo-controlled study evaluated a multi-species probiotic mixture containing strains from several Lactobacillus-related groups, Bifidobacterium species and Streptococcus thermophilus in adults with IBS. The study reported changes in the abundance of several administered microorganisms and a difference in diarrhoea-related symptom scores. However, the difference in overall symptom relief was not statistically significant [4].


This study illustrates an important point: a blend can affect measured microbial outcomes without necessarily demonstrating a significant improvement in every clinical endpoint.


Formulation considerations


A commercial Lactobacillus–Bifidobacterium blend requires:


  • Appropriate identification of each strain.

  • A clear scientific rationale for the combination.

  • Assessment of compatibility among the strains.

  • Defined viable-count specifications.

  • Suitable moisture and oxygen management.

  • Stability testing in the intended packaging.

  • Evidence supporting any proposed health claims.


Who should consider this category?


Supplement brands and manufacturers investigating multi-strain probiotic products may consider this category when the selected strains have appropriate supporting evidence.

Scientific verdict: A useful formulation strategy, but the quality of the specific combination matters more than the number of strains.


Blend No. 2: Multi-Strain Probiotic Formulations for IBS Research


What is irritable bowel syndrome?


Irritable bowel syndrome is a disorder of gut–brain interaction associated with symptoms that may include abdominal pain, bloating and altered bowel habits.


Its presentation varies. Some people experience predominantly diarrhoea, others predominantly constipation, and some experience a mixture of symptoms.

This variation makes it difficult to identify a single probiotic formulation suitable for every person with IBS.


Why are probiotic blends investigated for IBS?


Research has examined whether selected probiotics influence global IBS symptoms, abdominal pain, bloating and other outcomes.

However, results differ among formulations.


A systematic review and meta-analysis published in 2023 identified 82 eligible trials involving 10,332 participants. The review found that evidence varied according to the probiotic type and clinical outcome. For many combination products, the certainty of evidence was low or very low [5].


These findings do not mean that all multi-strain products are ineffective. They mean that a broad category such as “multi-strain probiotics” is too imprecise to establish efficacy.


What should a potential IBS formulation contain?


There is no universal ingredient list for an evidence-based IBS blend.

Instead, developers should identify the exact strain or combination investigated in relevant trials.


Potential research candidates include characterised strains from Bifidobacterium, Lactobacillus-related genera and selected other probiotic groups.


The following questions should guide selection:

  • Has the exact strain been studied in people with IBS?

  • Were the relevant IBS subtypes represented?

  • Which symptoms were measured?

  • Was the dose comparable to the proposed product?

  • Were the findings replicated?

  • Were adverse events reported?

  • Does the proposed product match the studied formulation?


Why do clinical findings differ?


Clinical trials can differ in participant selection, symptom definitions, intervention duration, probiotic composition and study quality.


For example, an improvement in abdominal pain does not necessarily demonstrate an improvement in bowel frequency or bloating.


Similarly, a positive finding for one multi-strain product cannot automatically substantiate a newly developed blend containing different strains.


For this reason, IBS-related probiotic development should be driven by a clearly defined outcome rather than a broad claim of “gut health.” Our guide to the best probiotics for gastrointestinal issues covers individual strains in more detail.


Scientific verdict: Multi-strain formulations are worth investigating for IBS, but evidence must be assessed product by product. Consumers with persistent or severe symptoms should seek appropriate medical evaluation rather than relying on supplements alone.


Blend No. 3: Formulations Investigated for Antibiotic-Associated Diarrhoea


Understanding antibiotic-associated diarrhoea


Antibiotics can disrupt the intestinal microbial ecosystem. In some individuals, this is associated with diarrhoea during or after antibiotic treatment.


Probiotics have been investigated as a potential preventive strategy in selected populations.

However, the evidence differs among strains, products, age groups and clinical circumstances.


Which probiotics have been studied?

Two frequently investigated probiotics are:


These are not interchangeable, and evidence for one should not automatically be applied to the other.


A meta-analysis of randomised controlled trials evaluating L. rhamnosus GG found an overall reduction in antibiotic-associated diarrhoea in the included population. In subgroup analyses, evidence was clearer in children than in adults, highlighting the importance of population-specific interpretation [6].


A network meta-analysis of 51 articles involving 9,569 participants also found evidence of differences among probiotic interventions. It did not establish that combining multiple strains is always superior to using a single strain [7].


Should manufacturers combine several probiotic strains?


Not automatically.

A blend intended for antibiotic-associated diarrhoea should be based on evidence for the particular combination and its intended population.


Adding multiple strains to a product containing an investigated strain does not automatically improve its effectiveness.


The manufacturer should consider:

  • The evidence for the selected strain or combination.

  • The intended age group.

  • The proposed viable dose.

  • Product stability.

  • Safety and tolerability.

  • The intended duration of use.

  • The relevant regulatory framework.


People receiving antibiotics should consult their healthcare professional about whether a probiotic is appropriate, particularly if they are seriously ill or immunocompromised.

Scientific verdict: This is a well-researched application area for certain specific probiotics, but the best-supported choice depends on the strain and population—not simply whether a product contains several microorganisms.


Blend No. 4: Bifidobacterium-Dominant Probiotic Blends


What are Bifidobacterium-dominant formulations?


Bifidobacterium-dominant formulations contain one or more selected strains from the genus Bifidobacterium.


These bacteria are important members of the human intestinal microbiota, although their abundance and distribution vary according to age, diet, health status and other factors.

Different Bifidobacterium species and strains have different physiological characteristics. They should not be treated as functionally identical.


Examples of species investigated in probiotic research include:

A formulation might contain one strain or combine several strains with different characteristics.


Why investigate Bifidobacterium blends?


Researchers investigate Bifidobacterium strains in relation to gastrointestinal function, microbial ecology and selected clinical outcomes.


However, the presence of a Bifidobacterium species in the human gut does not mean that every strain from that species will provide the same effect when consumed as a supplement.

Likewise, a higher Bifidobacterium count in a stool sample does not automatically establish improved health.


The relevant questions concern the properties of the administered strain, its survival and activity under appropriate conditions, and whether the formulation produces a meaningful benefit.


A systematic review of probiotic efficacy in IBS found that outcomes varied according to the specific strains and the symptoms being evaluated. The findings support a strain-specific approach rather than assuming that all Bifidobacterium products have equivalent effects [8].


How might a Bifidobacterium blend be formulated?

For product developers, possible approaches include:

  • Single-strain formulation: One characterised Bifidobacterium strain is selected for a defined application.

  • Multi-strain Bifidobacterium formulation: Two or more compatible strains are combined when the formulation has a clear scientific rationale.

  • Mixed-genus formulation: Selected Bifidobacterium strains are combined with strains from other relevant genera.

Each approach requires a separate assessment of identity, compatibility, viability, evidence and manufacturing feasibility.

Formulation considerations

Bifidobacterium strains may differ in oxygen sensitivity, moisture tolerance and storage stability. These properties should be considered when choosing processing conditions and packaging.

Manufacturers should also establish appropriate strain-specific specifications and ensure that the final product maintains the required viable count through its stated shelf life.

Scientific verdict: Bifidobacterium-dominant blends are a reasonable category for formulation research, but their quality depends on the selected strains and the evidence for the intended application.

Lactobacillus plantarum powder for Lactobacillus-dominant probiotic blends
In Lactobacillus-dominant blends, strain choice matters more than strain count.

Blend No. 5: Lactobacillus-Dominant Probiotic Blends

Understanding Lactobacillus-related probiotics

Lactobacillus-related microorganisms have been widely studied in food fermentation and probiotic research.

Because of the taxonomic revision of the former genus Lactobacillus, current scientific literature includes several related genera. Product developers should use accurate, current taxonomic names while retaining historical names where needed to make older studies identifiable.

Examples of organisms investigated in probiotic research include:

The choice of strain depends on the intended application and available evidence. See our comparison of which Lactobacillus probiotic is best for different uses.

What makes this category useful for product development?

A Lactobacillus-dominant formulation provides a broad platform for investigating selected strains with different technological and biological characteristics.

Potential research objectives may include gastrointestinal outcomes and other applications supported by strain-specific evidence.

For example, Lactiplantibacillus plantarum 299v has been investigated in clinical studies involving IBS symptoms. A systematic review and meta-analysis identified evidence of benefit for certain outcomes, while also noting limitations in the available research and variation in study quality [9].

This finding relates to a specific strain and does not establish that all Lactobacillus-dominant blends will provide the same results.

Should Lactobacillus strains be combined with one another?

They can be, provided the combination has a sound rationale.

Developers should consider whether the strains have complementary technical characteristics, whether they remain stable together and whether the combined formulation is supported by relevant evidence.

Potential issues include:

  • Different viable-count requirements.

  • Different oxygen sensitivities.

  • Variation in moisture tolerance.

  • Differences in processing stability.

  • The ability to distinguish strains during quality testing.

  • Whether the evidence supports the complete blend.

The presence of multiple Lactobacillus-related strains does not automatically demonstrate synergy.

Scientific verdict: Lactobacillus-dominant formulations offer considerable flexibility, but selecting the right strain is more important than choosing a high strain count.

Bacillus coagulans spore-forming probiotic powder
Spore-forming Bacillus strains can offer handling and stability advantages.

Blend No. 6: Spore-Forming Bacillus Probiotic Blends

What are spore-forming probiotics?

Certain Bacillus species can form spores, which may offer greater resistance to some environmental stresses than the vegetative cells of many other probiotic bacteria.

This characteristic has attracted interest in probiotic product development.

Depending on the strain, spore-forming microorganisms may offer practical advantages in handling, formulation and storage. However, the characteristics of one strain should not automatically be attributed to another.

Why are Bacillus probiotics investigated?

Selected Bacillus strains have been investigated for gastrointestinal applications, including IBS-related outcomes.

For example, a strain-specific systematic review and meta-analysis reported evidence for certain Bacillus coagulans strains in relation to selected IBS outcomes. However, the authors' conclusions were specific to the strains and outcomes studied [8].

This is important because the term Bacillus probiotic encompasses microorganisms with different characteristics.

A product containing one Bacillus strain cannot automatically use research findings from another strain as evidence of efficacy.

Can Bacillus strains be combined with Lactobacillus or Bifidobacterium?

Potentially, yes.

A formulation containing spore-forming and non-spore-forming microorganisms may be investigated when the selected ingredients have a clear scientific rationale. Our article on Bacillus vs Lactobacillus probiotics explains the key differences.

The combination must be assessed for compatibility, viable count, manufacturing performance, stability and safety.

Spore formation does not eliminate the need for quality control or appropriate safety assessment.

Safety considerations

Strain identification is particularly important when selecting Bacillus ingredients.

Manufacturers should establish the identity of the strain, review relevant safety data, verify microbiological quality and ensure that the ingredient is suitable for its intended use.

Supplier documentation should be evaluated rather than relying solely on general claims about spore-forming probiotics.

Scientific verdict: Bacillus-based formulations may be useful in selected applications, but their suitability depends on strain-specific evidence, safety and manufacturing quality.

Blend No. 7: Bacterial–Yeast Probiotic Formulations

What is a bacterial–yeast formulation?

Most commercial probiotic blends focus on bacteria. Some formulations also incorporate a characterised probiotic yeast.

One extensively investigated example is Saccharomyces boulardii.

Unlike bacterial probiotics, this organism is a yeast. Its different biological characteristics can make it relevant to specific formulation strategies.

However, combining a yeast with bacterial strains should not be assumed to improve a product's efficacy.

What does the clinical evidence show?

Research has investigated S. boulardii in gastrointestinal applications, including the prevention of antibiotic-associated diarrhoea.

The evidence is specific to the organism, preparation, dose, population and clinical outcome studied.

A systematic review of antibiotic-associated diarrhoea research identified S. boulardii among the probiotic interventions with supporting evidence, while also noting that the results of different probiotic preparations cannot automatically be generalised [10].

This does not mean that adding S. boulardii to any bacterial probiotic blend will improve the outcome.

What should manufacturers consider?

Bacterial–yeast formulations require attention to:

  • Identity and traceability of each microorganism.

  • Appropriate viable-count specifications.

  • Compatibility during storage.

  • Packaging requirements.

  • Stability of the finished formulation.

  • Safety and suitability for the intended population.

  • Clinical evidence for the actual combination.

The manufacturer should also ensure that the quality-control methods can adequately assess the different microorganisms in the finished product.

Scientific verdict: Bacterial–yeast formulations are worth considering when the intended application and evidence justify them. Adding a yeast solely to make a product appear more comprehensive is not a sufficient scientific rationale.

Blend No. 8: Paediatric Probiotic Formulations

Why do paediatric formulations require a separate approach?

Probiotic products intended for children should not be treated as interchangeable with products designed for adults.

Age, developmental stage, clinical indication, dose and safety considerations can affect product selection.

Evidence for an adult formulation does not automatically establish its suitability for infants or children.

Paediatric probiotic research has investigated several specific strains and combinations for defined gastrointestinal applications.

For example, research and professional recommendations have evaluated selected probiotics for the prevention of antibiotic-associated diarrhoea in children. These recommendations distinguish specific strains from other preparations that have insufficient supporting evidence [11].

What should a paediatric blend contain?

There is no single universally appropriate paediatric probiotic blend.

Selection should be based on:

  • The child's age.

  • The specific clinical or nutritional objective.

  • The exact strains studied.

  • The dose and duration used in relevant research.

  • Safety and tolerability.

  • The dosage form and ease of administration.

  • The quality of the finished product.

A manufacturer should avoid using broad statements such as “safe for all children” without appropriate evidence and regulatory review.

What about premature infants?

Premature infants, especially those with significant medical complications, represent a specialised population.

Some probiotic combinations have been investigated in neonatal research, but the findings and recommendations are specific to the strains, formulations and clinical settings studied.

Products intended for premature infants require particularly careful safety evaluation, clinical oversight and manufacturing controls.

Scientific verdict: Paediatric formulations must be selected for a defined age group and application. Adult probiotic research is not sufficient to justify a paediatric product.

Blend No. 9: Probiotic–Prebiotic Synbiotic Formulations

What is a synbiotic?

A synbiotic combines live microorganisms with substrate or substrates that are selectively utilized by host microorganisms and that confer a health benefit.

The internationally recognised definition distinguishes between complementary and synergistic synbiotics. In a complementary synbiotic, the probiotic and prebiotic components contribute to a health benefit without necessarily functioning cooperatively. In a synergistic synbiotic, the substrate is selected for utilization by the co-administered microorganism [12].

This distinction matters because a product containing probiotics and a prebiotic ingredient does not automatically satisfy the scientific criteria for a synbiotic. Read more in our guide to probiotic blends vs synbiotic blends.

Which prebiotic ingredients are investigated?

Examples include:

  • Inulin.

  • Fructooligosaccharides (FOS).

  • Galactooligosaccharides (GOS).

  • Certain resistant starches.

  • Other substrates investigated for selective microbial utilization.

The appropriate choice depends on the microorganisms, the intended formulation, the target population and the supporting evidence.

The ISAPP consensus statement on prebiotics explains why selective utilization and health benefit are central to the definition [13].

Why develop a synbiotic rather than a probiotic-only blend?

A synbiotic may be worth investigating when the substrate has a clear scientific purpose within the formulation.

For example, a manufacturer may seek to combine a characterised probiotic with a substrate that is selectively utilized by relevant microorganisms.

The formulation should then be assessed for:

  • Ingredient compatibility.

  • Substrate characteristics.

  • Viable-cell potency.

  • Gastrointestinal tolerance.

  • Stability.

  • Evidence for the intended benefit.

  • Regulatory suitability.

The addition of a prebiotic can also affect powder properties, capsule fill weight, taste and moisture management.

What evidence is required?

For a complementary synbiotic, the relevant components and combined formulation must satisfy the applicable scientific criteria.

For a synergistic synbiotic, the manufacturer must additionally establish selective utilization of the substrate by the co-administered microorganism.

In both cases, the intended health benefit must be substantiated.

Scientific verdict: Synbiotic formulations can be scientifically valuable, but their quality depends on the rationale and evidence supporting the complete formulation—not merely the presence of probiotics and prebiotics.

Blend No. 10: Clinically Substantiated, Application-Specific Probiotic Blends

The tenth category is best understood as a development strategy rather than a particular combination of microorganisms.

A clinically substantiated, application-specific blend is designed around a clearly defined outcome and supported by evidence relevant to the actual formulation.

This approach is particularly important for supplement brands seeking to develop differentiated products, as explained in our guide to custom probiotic blends.

Start with the intended outcome

The development process should begin with a specific research or product objective.

Examples might include investigating a defined gastrointestinal symptom or evaluating a formulation in a particular population.

The objective should be narrow enough to guide ingredient selection and determine which clinical outcomes are relevant.

A broad concept such as “complete gut health” is generally less useful for scientific formulation design than a clearly defined research question.

Identify the evidence

Once the objective is established, the development team should search for clinical studies involving the relevant strains or combinations.

PubMed and Europe PMC are useful for identifying published research. Nature and ScienceDirect provide access to articles from relevant journals, while ClinicalTrials.gov can help identify registered studies.

A comprehensive review should distinguish among:

  • Laboratory and mechanistic studies.

  • Animal research.

  • Human observational studies.

  • Randomised controlled trials.

  • Systematic reviews and meta-analyses.

  • Clinical guidelines and regulatory assessments.

Each type of evidence has a different role.

Develop the formulation

The development team should select ingredients according to their identity, supporting evidence, compatibility and manufacturing feasibility.

The final formulation should have defined specifications for:

  • Strain identity.

  • Viable count.

  • Ingredient composition.

  • Microbiological quality.

  • Storage conditions.

  • Shelf life.

  • Packaging.

  • Relevant analytical methods.

The complete formulation should be evaluated rather than assuming that evidence for its individual ingredients establishes the performance of the combined product.

Confirm the intended use

The final product should be evaluated for its intended market and target population.

Where appropriate, the development programme may require clinical research on the finished formulation.

Health claims and product labelling should be reviewed against the requirements of the destination market.

Scientific verdict: The strongest development strategy is not to select the largest number of strains. It is to select a suitable combination, establish appropriate quality specifications and build a defensible evidence base for the intended application.

How to Select the Best Probiotic Blend for a Specific Need

The ten categories above illustrate why probiotic selection should be based on a clearly defined objective.

The following framework can help consumers, healthcare professionals and manufacturers evaluate their options.

Selection criterion

Questions to ask

Why it matters

Intended application

What outcome is the product designed to address?

Determines which evidence is relevant

Strain identity

Are the strains adequately characterised?

Helps establish traceability and evidence relevance

Clinical evidence

Has the exact strain or combination been studied?

Helps distinguish established findings from assumptions

Dose

Is the proposed dose consistent with the relevant evidence?

Influences comparability with studied formulations

Quality

Are identity, viable count and microbiological specifications documented?

Supports product consistency

Stability

Is the required viable count maintained through shelf life?

Helps ensure the product meets its specifications

Safety

Is the formulation appropriate for the intended population?

Helps identify relevant risks and limitations

Regulatory status

Are the ingredients and claims suitable for the destination market?

Supports compliant product development

Manufacturing

Can the formulation be produced consistently?

Determines commercial feasibility

Value

Does the product provide a clear, evidence-based reason for its composition?

Helps buyers evaluate meaningful differentiation

Is a higher CFU count always better?

No.

CFU measures viable microorganisms capable of forming colonies under specified test conditions. It is a potency measure, not a universal measure of clinical effectiveness.

A higher CFU count does not automatically produce a greater health benefit. The relevant dose depends on the strain, formulation and intended use.

Manufacturers should establish specifications based on appropriate evidence and ensure that the declared potency is maintained throughout shelf life.

Are more strains always better?

No.

A larger number of strains can increase formulation complexity and create additional compatibility and quality-control requirements.

A multi-strain formulation may be useful when the combination has a sound scientific rationale. A single-strain formulation may be preferable when the evidence supports it and the intended product does not require additional microorganisms.

Are refrigerated probiotics always superior?

No.

Some probiotic products require refrigeration, while others can remain stable under specified room-temperature conditions.

Storage requirements depend on the microorganisms, formulation, packaging and stability data.

Consumers and buyers should follow the manufacturer's validated storage instructions rather than assuming that refrigeration is a universal indicator of quality.

Are all probiotic products safe for everyone?

No probiotic should be assumed suitable for every individual.

Many probiotic products are well tolerated by generally healthy people, but safety depends on the microorganism, product quality and intended population.

People who are severely ill, significantly immunocompromised or otherwise medically vulnerable should consult an appropriate healthcare professional before using probiotics. Extra caution is warranted for premature infants and other specialised populations.

Bifidobacterium lactis bulk probiotic powder for blend manufacturing
Compatibility, uniformity and stability testing turn a good formula into a reliable product.

Manufacturing the Top Probiotic Blends: A Quality-Focused Approach

Identifying suitable strains is only the first stage of probiotic product development. Manufacturers must also establish that the selected microorganisms can be processed, combined, packaged and stored without unacceptable loss of quality.

For B2B buyers, these considerations are important when assessing suppliers and comparing technically similar products.

Raw-material qualification

The manufacturing process should begin with appropriate qualification of each probiotic ingredient.

The supplier's documentation should establish the ingredient's identity, strain designation, potency, microbiological quality and storage requirements.

Additional considerations may include the material's moisture characteristics, physical properties and suitability for the intended dosage form.

The qualification process should be proportionate to the ingredient's intended use and the applicable quality requirements.

Strain compatibility

A multi-strain blend should be evaluated for compatibility before commercial production.

Different microorganisms may have different sensitivities to environmental conditions. Some strains may be more sensitive to oxygen, moisture or temperature than others.

The development team should determine whether the strains can be blended and stored together while maintaining the required specifications.

A combination that is scientifically interesting may not be technically suitable if one strain loses viability more rapidly than the others.

Blending uniformity

Uniformity is important because the finished product must consistently meet its declared composition and potency requirements.

Manufacturers should establish suitable blending procedures and determine whether the selected process produces a consistent mixture.

The required controls depend on the formulation, batch size, ingredient properties and dosage form.

Stability and shelf life

Stability studies should assess the finished product under appropriate storage conditions.

Relevant variables include:

  • Viable-cell count.

  • Moisture and water activity.

  • Packaging integrity.

  • Temperature and humidity.

  • Oxygen exposure.

  • Physical properties.

  • Changes in relevant ingredient characteristics.

For products intended for international distribution, stability assessments should consider the anticipated storage and transport conditions.

The shelf life should be supported by appropriate data rather than based solely on the stability of individual raw materials.

Packaging and storage

Probiotic formulations may be supplied in capsules, sachets, bottles, blister packs or other suitable formats, including ready-to-fill blends for supplement manufacturers.

The choice depends on the formulation's characteristics, required dose, packaging performance and intended market.

A packaging system should be selected to protect the product under its specified storage conditions.

For B2B customers, the supplier should communicate the relevant storage instructions and provide supporting documentation when required.

Scientific documentation

A technically strong probiotic product should have a clear documentation package.

This may include:

  • Technical data sheet.

  • Certificate of Analysis.

  • Strain identification records.

  • Viable-count specifications.

  • Microbiological quality results.

  • Safety documentation.

  • Stability data.

  • Storage and handling instructions.

  • Relevant scientific references.

  • Market-specific regulatory information.

The precise requirements vary according to the ingredient and destination market.

For a finished formulation supported by clinical research, the documentation should also identify how the evidence relates to the proposed product.

Scientific Evidence and Regulatory Compliance: What Manufacturers Must Know

Scientific evidence and regulatory compliance are separate but closely related requirements.

A study may support a scientific hypothesis without authorising a particular commercial health claim. Similarly, a formulation may contain well-characterised ingredients but still lack evidence for the benefit claimed for the finished product.

The role of EFSA

The European Food Safety Authority assesses the scientific substantiation of health claims under the applicable European framework.

A proposed claim must meet the relevant legal requirements, and the scientific evidence must support the relationship between the food or ingredient and the claimed benefit [14].

For probiotic manufacturers, this means that claims should not be based merely on the number of strains or the presence of a familiar probiotic species.

A manufacturer targeting the European market should review the applicable authorisations, conditions of use, labelling requirements and relevant national or EU rules before making a claim.

The role of ClinicalTrials.gov

ClinicalTrials.gov provides a searchable registry of clinical studies.

Manufacturers can use it to identify trials involving particular strains, combinations, health outcomes and populations.

However, trial registration is not proof of efficacy.

When reviewing a study, check:

  • Whether it has started or been completed.

  • Whether results are available.

  • Whether the results have been published.

  • Whether the formulation matches the proposed product.

  • Whether the findings are relevant to the intended claim.

  • Whether the study design and analysis support the conclusions.

The role of PubMed and Europe PMC

PubMed and Europe PMC are useful for identifying peer-reviewed research, systematic reviews and clinical trials.

Searches should include the strain designation wherever possible, rather than relying only on a species or genus name.

For example, a search for a specific L. rhamnosus strain may provide more relevant evidence than a search for Lactobacillus alone.

Researchers should also review the methods, results and limitations of each study instead of relying exclusively on abstracts or commercial summaries.

The role of Nature and ScienceDirect

Nature and ScienceDirect provide access to scientific articles, reviews and other research publications.

They can help researchers investigate probiotic mechanisms, formulation technologies, microbial interactions and clinical evidence.

However, the reputation of a publisher does not remove the need to assess the quality and relevance of an individual paper.

The formulation, population, outcomes and study design should remain central to the evaluation.

Source Probiotic Blends From Swiss Medicare Probiotics

Swiss Medicare Probiotics manufactures bulk probiotic strains and probiotic blends for supplement, functional food and private-label brands, including Lactobacillus, Bifidobacterium and Bacillus strains, with custom formulation support. Contact our team to discuss your blend.

Related Reading

Frequently Asked Questions About the Top 10 Best Probiotic Blends

1. What are the top 10 best probiotic blends?

There is no universally accepted ranking of the ten best probiotic blends. Useful categories to investigate include Lactobacillus–Bifidobacterium blends, multi-strain gastrointestinal formulations, selected formulations studied for antibiotic-associated diarrhoea, Bifidobacterium-dominant blends, Lactobacillus-dominant blends, Bacillus-based formulations, bacterial–yeast combinations, paediatric formulations, synbiotics and clinically substantiated application-specific blends.

The best choice depends on the intended use and evidence for the exact formulation.

There is no single best blend for everyone. Different products have been studied for different outcomes, and evidence for one formulation cannot automatically be applied to another.

A suitable choice should be based on the intended outcome, strain identity, dose, safety, quality and available clinical evidence.

Not necessarily. Some multi-strain formulations have demonstrated benefits in specific studies, while other formulations have produced inconsistent results.

The number of strains is not an independent measure of efficacy. A single-strain product may be suitable when the selected strain has relevant supporting evidence.

Frequently studied microorganisms include Lacticaseibacillus rhamnosus GG, selected Bifidobacterium strains, Lactiplantibacillus plantarum 299v and Saccharomyces boulardii.

The amount and quality of evidence differ by strain and application. Being extensively studied does not mean a strain is suitable for every health outcome.

Research includes L. rhamnosus GG and S. boulardii, among other preparations.

The evidence varies by population and study design. People taking antibiotics should consult their healthcare professional about whether a probiotic is appropriate for them.

Some probiotic strains and combinations have been investigated for IBS symptoms, including abdominal pain and bloating.

However, evidence is inconsistent across formulations and outcomes. A product's effectiveness should not be inferred from the general category of multi-strain probiotics.

Not necessarily. CFU measures viable microorganisms under specified testing conditions. A higher count does not automatically establish greater clinical effectiveness.

The appropriate dose depends on the strain, formulation and intended use.

Selected strains from these groups can be combined in a probiotic formulation. However, their compatibility and the efficacy of the finished combination must be assessed.

The genus names alone do not establish that a combination will be effective.

A probiotic blend combines selected live microorganisms. A synbiotic combines live microorganisms with selectively utilized substrates and must satisfy the scientific criteria for its intended category.

Adding a prebiotic ingredient to a probiotic product does not automatically establish that the resulting product is a substantiated synbiotic.

Neither group is universally better. Selected Bacillus strains may offer useful technological characteristics, while particular Lactobacillus-related strains have been investigated for specific clinical applications.

The appropriate comparison is between the exact strains and formulations, not the genera as a whole.

Some probiotics have been investigated for specific paediatric applications. However, suitability depends on the child's age, the strain, the intended use and the supporting evidence.

Products designed for adults should not automatically be assumed suitable for children. Parents and caregivers should seek appropriate medical advice when considering probiotics for infants or children with medical conditions.

No. Although many probiotic products are well tolerated by generally healthy people, suitability depends on the individual and the product.

People who are severely ill, significantly immunocompromised or medically vulnerable should seek healthcare advice before using probiotics.

Manufacturers should assess strain identity, safety, clinical evidence, viable-count specifications, compatibility, stability, manufacturing feasibility and regulatory suitability.

The evaluation should relate to the actual formulation and its intended use.

Buyers should consider requesting a technical data sheet, Certificate of Analysis, strain identification records, viable-count specifications, microbiological quality results, safety documentation, stability data and relevant scientific references.

Additional documentation may be required depending on the destination market and the intended application.

A scientifically justified formulation begins with a defined product objective. Developers should then select suitable strains, evaluate compatibility, establish quality specifications and determine whether the available evidence supports the intended use.

Differentiation should be based on meaningful formulation characteristics and evidence rather than simply increasing the number of strains.

The most important factor is whether the exact formulation is appropriate for the intended application and supported by relevant evidence.

Strain identity, dose, quality, safety and stability all contribute to the suitability of the finished product.

Scientific References

Numbering corresponds to the citations in the text.

[1] Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014;11:506–514. PubMed | Nature

[2] McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: A systematic review and meta-analysis. Frontiers in Medicine. 2018. PubMed

[3] Zheng J, Wittouck S, Salvetti E, et al. A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. International Journal of Systematic and Evolutionary Microbiology. 2020;70:2782–2858. PubMed

[4] Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. PubMed

[5] Ford AC, et al. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. American Journal of Gastroenterology. 2023. PubMed

[6] Szajewska H, Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Alimentary Pharmacology & Therapeutics. 2015;42:1149–1157. PubMed

[7] Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. PubMed

[8] Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. PubMed

[9] Lactiplantibacillus plantarum 299v and IBS research (evidence included in the review cited in Reference 8). PubMed | Europe PMC search

[10] Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PubMed

[11] Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. PubMed

[12] Swanson KS, Gibson GR, Hutkins R, et al. The ISAPP consensus statement on the definition and scope of synbiotics. Nature Reviews Gastroenterology & Hepatology. 2020;17:687–701. PubMed | PubMed Central full text

[13] Gibson GR, Hutkins R, Sanders ME, et al. The ISAPP consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology. 2017;14:491–502. PubMed | Nature

[14] European Food Safety Authority. Health claims and scientific substantiation. EFSA health claims | EFSA Article 13 health claims

 
 
 

Comments


bottom of page